Article
Dermatology
A. Lamberts, N. Kotnik, G. F. H. Diercks, J. M. Meijer, G. Di Zenzo, H. H. Pas, M. F. Jonkman, B. F. Gibbs, U. Raap, B. Horvath
Summary: Total IgE levels were elevated in a significant percentage of both NBP and BP patients, with IgE being present in both serum and skin. The study suggests a common IgE-dependent mechanism in both diseases, such as pruritus, but further research is needed to determine if IgE contributes to blister formation in BP.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
Florine Guerrois, Elsa Hassan, Thomas Bettuzzi, Vannina Seta, Claire Goulvestre, Lamia Jelti, Thibaut Belmondo, Pierre Wolkenstein, Selim Aractingi, Saskia Ingen-Housz-Oro, Nicolas Dupin
Summary: The study identified three different clusters of BP, including one corresponding to severe BP1801 BP230- BP with features common to mucous membrane pemphigoid.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Dermatology
Florine Guerrois, Elsa Hassan, Thomas Bettuzzi, Vannina Seta, Claire Goulvestre, Lamia Jelti, Thibaut Belmondo, Pierre Wolkenstein, Selim Aractingi, Saskia Ingen-Housz-Oro, Nicolas Dupin
Summary: This study identifies three different clusters of Bullous pemphigoid (BP), one of which has common features with mucous membrane pemphigoid. Understanding the different clinical and biological profiles of BP is crucial in the diagnosis and treatment of the disease.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Dermatology
Lula Maria Nieto-Benito, Marta Bergon-Sendin, Ana Pulido-Perez, Angel Manuel Rosell-Diaz, Veronica Parra-Blanco, Ricardo Suarez-Fernandez
Summary: A retrospective study found that DPP4i-induced BP cases are characterized by generalized lesions and scalp involvement, while gliptin-related BP cases are associated with a decrease in eosinophilic infiltrate and lower concentrations of anti-BP180 IgG.
EXPERIMENTAL DERMATOLOGY
(2021)
Article
Dermatology
Sascha Staender, Enno Schmidt, Detlef Zillikens, Ralf J. Ludwig, Khalaf Kridin
Summary: Some patients with bullous pemphigoid have mucosal involvement, which is associated with the absence of anti-BP230 antibodies and peripheral eosinophilia.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2021)
Article
Immunology
Roberto Maglie, Maria Efenesia Baffa, Francesca Montefusco, Carlo Pipito, Stefano Senatore, Marco Capassoni, Vincenza Maio, Marco Matucci Cerinic, Emiliano Antiga, Serena Guiducci
Summary: This article describes the unusual occurrence of bullous pemphigoid (BP) in a female patient with a concomitant history of generalized morphea and cutaneous and genital lichen sclerosus. The study provides a literature review on cases of BP in patients with localized scleroderma or lichen sclerosus and discusses the immunological mechanisms that may have contributed to the emergence of BP in the patient.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Dermatology
Yen-Chi Shih, Huijie Yuan, Jia Shen, Jie Zheng, Meng Pan
Summary: The study found that anti-BP230 IgE is more frequently observed in topical-steroid-therapy-resistant patients with bullous pemphigoid, and it prefers the R1 domain of BP230, which is not included in commercially available testing kits. Detection of anti-BP230 IgE can serve as an indicator for initiating systemic steroid therapy.
JOURNAL OF DERMATOLOGY
(2021)
Article
Medicine, General & Internal
Francesco Moro, Feliciana Mariotti, Anna Pira, Naomi De Luca, Biagio Didona, Gianluca Pagnanelli, Giovanni Di Zenzo
Summary: This article reports a case of a patient with multiple sclerosis and scleroderma who developed severe bullous pemphigoid. The disease may be triggered by an immune response to BP180 and BP230.
FRONTIERS IN MEDICINE
(2022)
Article
Immunology
Dario Didona, Luca Scarsella, Milad Fehresti, Farzan Solimani, Hazem A. Juratli, Manuel Goebel, Stefan Muehlenbein, Lily Holiangu, Josquin Pieper, Vera Korff, Thomas Schmidt, Cassian Sitaru, Ruediger Eming, Michael Hertl, Robert Pollmann
Summary: Bullous pemphigoid is an autoimmune disorder in elderly individuals characterized by serum IgG autoantibodies. Chronic pruritus in the elderly may be related to autoimmunity, and therapeutic application of clobetasol propionate ointment in BP patients has been shown to reduce BP180-specific T cells and improve symptoms.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Dermatology
Gilles Battesti, Charline Garcia, Manuelle Viguier, Valentine Marchal, Marion Castel, Pascal Joly, Anne-Pham Ledard, Maria-Polina Konstantinou, Vannina Seta, Nadege Cordel, Sophie Duvert-Lehembre, Emmanuelle Tancrede-Bohin, Thibaut Belmondo, Saskia Ingen-Housz-Oro, Michel d'Incan
Summary: This study evaluated the impact of immunologic-based decision on the relapse rates in patients with bullous pemphigoid after treatment cessation. The results showed that the relapse rates after 3 and 6 months were not significantly reduced with immunologic-based decision compared to the traditional clinical-based decision.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Dermatology
S. Staender, E. Schmidt, D. Zillikens, D. Thaci, R. J. Ludwig, K. Kridin
Summary: Patients with both BP and psoriasis present at a younger age with a milder disease phenotype, lower levels of pathogenic autoantibodies, and specific linear C3 deposits along the dermal-epidermal junction detected by direct immunofluorescence microscopy.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
W. Masmoudi, M. Vaillant, S. Vassileva, A. Patsatsi, G. Quereux, C. Moltrasio, C. Abasq, C. Prost-Squarcioni, D. Kottler, D. Kiritsi, N. Litrowski, P. Plantin, L. Friedrichsen, A. Zebrowska, S. Duvert-Lehembre, S. Hofmann, V Ferranti, F. Jouen, P. Joly, V Hebert
Summary: This study suggests cut-off values of 20-57 for BPDAI to distinguish mild, moderate and severe BP, and confirms that it is a robust tool to assess BP severity precisely. The intraclass correlation coefficient for BPDAI was high, and improvement in BPDAI score was correlated with decrease in anti-BP180 ELISA value.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Review
Immunology
Connor Cole, Keshavamurthy Vinay, Luca Borradori, Kyle T. Amber
Summary: Bullous pemphigoid is an autoimmune blistering disease caused by autoantibodies. While typically considered complement-mediated, recent evidence suggests complement-independent mechanisms may also contribute to tissue damage and blister formation, opening new perspectives for targeted treatments.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Meital Oren-Shabtai, Daniel Mimouni, Adi Nosrati, Lihi Atzmony, Baruch Kaplan, Aviv Barzilai, Sharon Baum
Summary: This study describes the clinical and immunological features of patients with recalcitrant BP treated with immunobiological therapies. The results show that the use of biological treatment can significantly improve the condition of BP patients and has no adverse events.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Carlo Alberto Maronese, Marzia Caproni, Chiara Moltrasio, Giovanni Genovese, Pamela Vezzoli, Paolo Sena, Giulia Previtali, Emanuele Cozzani, Giulia Gasparini, Aurora Parodi, Laura Atzori, Emiliano Antiga, Roberto Maglie, Francesco Moro, Elena Biancamaria Mariotti, Alberto Corra, Sabatino Pallotta, Biagio Didona, Angelo Valerio Marzano, Giovanni Di Zenzo
Summary: Bullous pemphigoid (BP) is an autoimmune disease that COVID-19 vaccines may induce. An Italian study collected data of BP patients associated with COVID-19 vaccines and found that these patients have similar characteristics to idiopathic BP, but with a slight male predominance and reduced humoral response to BP230.
FRONTIERS IN MEDICINE
(2022)
